Jonathan Davis
Consultant and Advisor Helix Biotech
Seminars
Monday 23rd February 2026
Panel Discussion: What’s the New Path to the Next Generation of ADCs?
10:30 am
- Understanding how to migrate from non-selective ADC payloads
- Debating the right properties for a next generation payload and linker: Can (or should?) any small molecule therapeutic be developed into an ADC?
- Debating the right strategy for dual-payload ADCs
- Understanding ADC toxicity and developability for next-generation conjugates
Panel Session Hosted By:
Wednesday 25th February 2026
Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies
2:00 pm
- Examining CEACAM6 as a tumour-specific target in hard-to-treat solid tumours
- Leveraging cutting edge ADC design to achieve precise targeting with broad therapeutic potential
- Building state-of-the-art ADC constructs targeting CEACAM6
